Role of anlotinib plus albumin paclitaxel regimen in stage IV non-small cell lung cancer and mental state

Figure 1 Serum marker levels. A: Carcinoembryonic antigen; B: Cytokeratin 19 fragment antigen 21-1; C: Vascular endothelial growth factor. ^aP < 0.05 vs pre-treatment, ^bP < 0.05 vs conventional therapy. CEA: Carcinoembryonic antigen; Cyfra21-1: Cytokeratin 19 fragment antigen 21-1; VEGF: Vascular endothelial growth factor.

Figure 2 Comparison of progression-free survival and overall survival. A: Progression-free survival; B: Overall survival. PFS: Progression-free survival; OS: Overall survival. ^aP < 0.05 vs conventional therapy.

Figure 3 Contrast of immune function. A: CD3⁺; B: CD4⁺; C: CD4⁺/CD8⁺. ^aP < 0.05 vs pre-treatment, ^bP < 0.05 vs conventional therapy.

Figure 4 Quality of life. ^aP < 0.05 vs pre-treatment, ^bP < 0.05 vs conventional therapy.

Figure 5 Mental state. A: Self Rating Anxiety Scale; B: Self Rating Depression Scale. ^aP < 0.05 vs conventional therapy. SAS: Self Rating Anxiety Scale; SDS: Self Rating Depression Scale.